Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.

MLA

Wu, Jiong, et al. “Neoadjuvant Pyrotinib, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer (PHEDRA): A Double-Blind, Randomized Phase 3 Trial.” BMC Medicine, vol. 20, no. 1, Dec. 2022, p. 498. EBSCOhost, https://doi.org/10.1186/s12916-022-02708-3.

APA

Wu, J., Jiang, Z., Liu, Z., Yang, B., Yang, H., Tang, J., Wang, K., Liu, Y., Wang, H., Fu, P., Zhang, S., Liu, Q., Wang, S., Huang, J., Wang, C., Wang, S., Wang, Y., Zhen, L., Zhu, X., … Zou, J. (2022). Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Medicine, 20(1), 498. https://doi.org/10.1186/s12916-022-02708-3

Chicago

Wu, Jiong, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, et al. 2022. “Neoadjuvant Pyrotinib, Trastuzumab, and Docetaxel for HER2-Positive Breast Cancer (PHEDRA): A Double-Blind, Randomized Phase 3 Trial.” BMC Medicine 20 (1): 498. doi:10.1186/s12916-022-02708-3.